a. Administration set with inline filter of 120- to

170-mm pore size to be used for all products

b. Microaggregate filter, 20- to 40- mm pore size

(1) Must follow manufacturer’s instructions

(2) Some function only if product is dripped

(3) Not advisable for syringe administration

(4) Usefulness questionable and unnecessary if LD

and/or additive RBCs used

c. Prestorage LD (2,4,5)

(1) Removes 99.9% of white blood cells (WBCs), or

3 log LD

(2) Must follow manufacturer’s instructions

(3) Attenuation/abrogation of CMV and other

viruses such as Epstein–Barr virus (EBV) and

human T-lymphotropic virus (HTLV) I/II harbored in WBCs

(4) Prestorage LD (performed by collecting facility)

preferred to post-storage (bedside) LD

4. Sterile syringe

5. Blood administration set

a. May be manufactured with integral 120- to 170-mm

filter

Table 43.1 Clinical Indications for Irradiated

Blood Components (2,56)

1. Intrauterine transfusion (IUT) or postnatal transfusion in neonate who

had received IUT

2. Premature infants, variably defined by weight and postgestational age

3. Congenital immunodeficiency suspected or confirmed

4. Undergoing exchange transfusion for erythroblastosis

5. Hematologic/solid organ malignancy

6. Recipient of familial blood donation

7. Recipient of HLA-matched or cross-match–compatible platelets or

granulocytes

From Josephson CD. Neonatal and pediatric transfusion practice. In: Roback JD,

eds. Technical Manual of the American Association of Blood Banks. 16th ed.

Bethesda, MD: American Association of Blood Banks; 2008:639; Roseff SD, Luban

NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion.

Transfusion. 2002;42:1398.